PortfoliosLab logoPortfoliosLab logo
ATNM vs. CCCC
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ATNM vs. CCCC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Actinium Pharmaceuticals, Inc. (ATNM) and C4 Therapeutics, Inc. (CCCC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ATNM achieves a -24.26% return, which is significantly lower than CCCC's 115.71% return.


ATNM

1D
0.00%
1M
-12.71%
YTD
-24.26%
6M
-35.63%
1Y
-31.33%
3Y*
-48.43%
5Y*
-33.26%
10Y*
-32.39%

CCCC

1D
-0.72%
1M
15.73%
YTD
115.71%
6M
97.13%
1Y
190.14%
3Y*
12.55%
5Y*
-35.79%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ATNM vs. CCCC - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
ATNM
Actinium Pharmaceuticals, Inc.
-24.26%7.94%-75.20%-52.30%77.20%-22.95%-16.49%
CCCC
C4 Therapeutics, Inc.
115.71%-46.94%-36.28%-4.24%-81.68%-2.81%24.55%

Correlation

The correlation between ATNM and CCCC is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.33

Correlation (3Y)
Calculated over the trailing 3-year period

0.33

Correlation (5Y)
Calculated over the trailing 5-year period

0.34

Correlation (All Time)
Calculated using the full available price history since Oct 2, 2020

0.34

Fundamentals

Market Cap

ATNM:

$32.17M

CCCC:

$519.43M

EPS

ATNM:

-$0.75

CCCC:

-$1.18

PS Ratio

ATNM:

357.14

CCCC:

12.65

PB Ratio

ATNM:

13.96

CCCC:

2.22

Total Revenue (TTM)

ATNM:

$90.00K

CCCC:

$28.71M

Gross Profit (TTM)

ATNM:

$485.00K

CCCC:

$26.90M

EBITDA (TTM)

ATNM:

-$24.68M

CCCC:

-$107.31M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ATNM vs. CCCC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATNM
ATNM Risk / Return Rank: 2020
Overall Rank
ATNM Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
ATNM Sortino Ratio Rank: 2222
Sortino Ratio Rank
ATNM Omega Ratio Rank: 2424
Omega Ratio Rank
ATNM Calmar Ratio Rank: 1717
Calmar Ratio Rank
ATNM Martin Ratio Rank: 1818
Martin Ratio Rank

CCCC
CCCC Risk / Return Rank: 8686
Overall Rank
CCCC Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
CCCC Sortino Ratio Rank: 8888
Sortino Ratio Rank
CCCC Omega Ratio Rank: 8383
Omega Ratio Rank
CCCC Calmar Ratio Rank: 8787
Calmar Ratio Rank
CCCC Martin Ratio Rank: 8282
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATNM vs. CCCC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Actinium Pharmaceuticals, Inc. (ATNM) and C4 Therapeutics, Inc. (CCCC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ATNMCCCCDifference
Sharpe ratioReturn per unit of total volatility

-2.38

Sortino ratioReturn per unit of downside risk

-3.30

Omega ratioGain probability vs. loss probability

0.96

1.32

-0.37

Calmar ratioReturn relative to maximum drawdown

-0.66

3.67

-4.33

Martin ratioReturn relative to average drawdown

-1.10

7.13

-8.23

ATNM vs. CCCC - Sharpe Ratio Comparison

The current ATNM Sharpe Ratio is -0.48, which is lower than the CCCC Sharpe Ratio of 1.90. The chart below compares the historical Sharpe Ratios of ATNM and CCCC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ATNM vs. CCCC - Drawdown Comparison

The maximum ATNM drawdown since its inception was -99.75%, roughly equal to the maximum CCCC drawdown of -97.82%. Use the drawdown chart below to compare losses from any high point for ATNM and CCCC.


Loading charts...

Drawdown Indicators


ATNMCCCCDifference

Max Drawdown

Largest peak-to-trough decline

-99.75%

-97.82%

-1.93%

Max Drawdown (1Y)

Largest decline over 1 year

-47.59%

-52.10%

+4.51%

Max Drawdown (3Y)

Largest decline over 3 years

-90.09%

-90.00%

-0.09%

Max Drawdown (5Y)

Largest decline over 5 years

-93.20%

-97.82%

+4.62%

Max Drawdown (10Y)

Largest decline over 10 years

-98.37%

Current Drawdown

Current decline from peak

-99.74%

-91.84%

-7.90%

Average Drawdown

Average peak-to-trough decline

-85.42%

-72.01%

-13.41%

Ulcer Index

Depth and duration of drawdowns from previous peaks

28.61%

26.79%

+1.82%

Volatility

ATNM vs. CCCC - Volatility Comparison

The current volatility for Actinium Pharmaceuticals, Inc. (ATNM) is 16.80%, while C4 Therapeutics, Inc. (CCCC) has a volatility of 27.58%. This indicates that ATNM experiences smaller price fluctuations and is considered to be less risky than CCCC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ATNMCCCCDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.80%

27.58%

-10.78%

Volatility (6M)

Calculated over the trailing 6-month period

45.16%

63.03%

-17.87%

Volatility (1Y)

Calculated over the trailing 1-year period

65.56%

101.00%

-35.44%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

79.87%

117.55%

-37.68%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

81.43%

112.85%

-31.42%

Dividends

ATNM vs. CCCC - Dividend Comparison

Neither ATNM nor CCCC has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ATNM vs. CCCC - Financials Comparison

This section allows you to compare key financial metrics between Actinium Pharmaceuticals, Inc. and C4 Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M2022202320242025202600
(ATNM) Total Revenue
(CCCC) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ATNM and CCCC have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CCCC has higher volatility (27.58%) compared to ATNM (16.80%). In terms of maximum drawdown, ATNM dropped -99.75% vs CCCC's -97.82%.

CCCC currently has the higher Sharpe Ratio (1.90 vs -0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ATNM and CCCC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer